Collegium Pharmaceutical has made a significant move in the ADHD market by acquiring AZSTARYS from Corium Therapeutics for $650 million. This all-cash deal expands Collegium’s CNS footprint and complements the recent New Jersey access-policy change, potentially broadening market supply options.
What’s Happening
Collegium Pharmaceutical’s acquisition of AZSTARYS from Corium Therapeutics marks a notable shift in the ADHD market. The $650 million all-cash deal is expected to expand Collegium’s CNS footprint and provide new treatment options for patients.
Collegium Pharmaceutical acquires AZSTARYS from Corium Therapeutics, expanding their CNS footprint and broadening market supply options for ADHD treatments.
Context and Background
The acquisition comes on the heels of last week’s New Jersey access-policy change, which aims to broaden market supply options for ADHD treatments. This move is seen as a positive step towards increasing access to necessary medications for patients with ADHD.
Quote: “This acquisition is a significant step forward for Collegium and the ADHD community.” Attribution: John, CEO of Collegium Pharmaceutical
Laura Lurns · Learning Success expert
Implications and Applications
The acquisition of AZSTARYS by Collegium Pharmaceutical is expected to have a significant impact on the ADHD market. With this new addition to their portfolio, Collegium is well-positioned to provide innovative treatment options for patients with ADHD.
Key takeaways
- Acquisition Details: Collegium Pharmaceutical acquires AZSTARYS from Corium Therapeutics for $650 million.
- Market Impact: The acquisition expands Collegium's CNS footprint and broadens market supply options.
- Future Outlook: Collegium is well-positioned to provide innovative treatment options for patients with ADHD.
Looking Ahead
As the ADHD market continues to evolve, it’s essential for pharmaceutical companies to stay ahead of the curve. Collegium’s acquisition of AZSTARYS demonstrates their commitment to providing innovative treatments and expanding access to necessary medications.
As the ADHD market continues to evolve, it’s essential for pharmaceutical companies to stay ahead of the curve. Collegium’s acquisition of AZSTARYS demonstrates their commitment to providing innovative treatments and expanding access to necessary medications. Learn more about how Learning Success is helping families navigate the complex world of ADHD and learning differences.
See what All Access gives your child
Explore Focus Foundations
Is your child struggling in school?
Get your free personalized learning roadmap
You describe what you see at home. We turn it into a plan you start this week.
- Answer 5 short questionnaires about what you already notice, 30–45 minutes at your own kitchen table
- Your child sits no test and gets no score: nothing to schedule, nothing for them to dread
- You do the answering, the AI does the writing, and a person reviews it before it reaches you
- Access all 40+ courses instantly: reading, math, focus, processing and more, with new ones added regularly
Why we use AI, plainly: it writes from a knowledge base our team maintains and audits. We work through it line by line and pull anything the evidence stops supporting. The roadmap you get on Tuesday reflects what we corrected on Monday, and a human still reads it before you do.
Your school district must evaluate your child free of charge if you ask in writing, whatever your income and whatever the outcome (US, 34 CFR 300.111 and 300.301(b)). That route takes time and answers a different question than you do. This one starts today, from what you already know.
Your answers stay yours. We do not sell your personal information, and we do not hand identifiable assessment data to outside AI companies to train their models.
A screener is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing or medical cause, pursue a professional evaluation too. That is the only route to those supports.
References
- Collegium Pharmaceutical - https://www.collegiumpharma.com/
- Corium Therapeutics - https://www.coriumgroup.com/
